(Q56974494)

Orso Maria Lucherini

6

0 references

Florenzo Iannone

Florenzo Iannone

8

0 references

Giovanni Lapadula

Giovanni Lapadula

7

0 references

Luca Cantarini

Luca Cantarini

1

0 references

Donato Rigante

5

Donato Rigante

0 references

Laura Coladonato

4

Laura Coladonato

0 references

author name string

Antonio Vitale

Immunology and functional genomics of Behçet's disease

3

0 references

publication date

15 April 2014

0 references

published in

Clinical Rheumatology

0 references

volume

34

0 references

issue

6

0 references

page(s)

1141-1143

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

A proposed classification of the immunological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Interferon therapy in rheumatic diseases: state-of-the-art 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Adalimumab: a new modality for Behçet's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

IL-6 deficiency exacerbates skin inflammation in a murine model of irritant dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Anakinra treatment in drug-resistant Behcet’s disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Cytokines and Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2589-Z

Behçet's disease: treatment of mucocutaneous lesions.

21 January 2018

1 reference

12 December 2020

Successful use of canakinumab in a patient with resistant Behçet's disease

1 reference

12 December 2020

A study of cytokines in burn blister fluid related to wound healing

1 reference

12 December 2020

Refractory neuro-Behçet treated by tocilizumab: a case report

1 reference

12 December 2020

A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet's syndrome.

1 reference

12 December 2020

Tocilizumab may be a potential addition to our weapons against neuro-Behçet’s disease

1 reference

12 December 2020

Safety and efficacy of etanercept in children with juvenile-onset Behcets disease.

1 reference

12 December 2020

Tocilizumab treatment for neuro-Behcet's disease, the first report

1 reference

12 December 2020

Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction

1 reference

12 December 2020